- Home
- AUST vs BLRX Comparison
AUST vs BLRX Comparison
Compare AUST & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- BLRX
- Stock Information
- Founded
- AUST 2020
- BLRX 2003
- Country
- AUST Canada
- BLRX Israel
- Employees
- AUST N/A
- BLRX N/A
- Industry
- AUST
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- BLRX Health Care
- Exchange
- AUST Nasdaq
- BLRX Nasdaq
- Market Cap
- AUST 15.5M
- BLRX 17.3M
- IPO Year
- AUST 2022
- BLRX 2011
- Fundamental
- Price
- AUST $1.25
- BLRX $0.11
- Analyst Decision
- AUST
- BLRX Strong Buy
- Analyst Count
- AUST 0
- BLRX 2
- Target Price
- AUST N/A
- BLRX $5.50
- AVG Volume (30 Days)
- AUST 92.5K
- BLRX 19.4M
- Earning Date
- AUST 03-03-2025
- BLRX 11-25-2024
- Dividend Yield
- AUST N/A
- BLRX N/A
- EPS Growth
- AUST N/A
- BLRX N/A
- EPS
- AUST N/A
- BLRX N/A
- Revenue
- AUST N/A
- BLRX $21,991,000.00
- Revenue This Year
- AUST N/A
- BLRX N/A
- Revenue Next Year
- AUST N/A
- BLRX N/A
- P/E Ratio
- AUST N/A
- BLRX N/A
- Revenue Growth
- AUST N/A
- BLRX N/A
- 52 Week Low
- AUST $0.62
- BLRX $0.08
- 52 Week High
- AUST $3.19
- BLRX $1.44
- Technical
- Relative Strength Index (RSI)
- AUST 46.23
- BLRX 32.10
- Support Level
- AUST $1.05
- BLRX $0.08
- Resistance Level
- AUST $1.27
- BLRX $0.14
- Average True Range (ATR)
- AUST 0.10
- BLRX 0.03
- MACD
- AUST 0.03
- BLRX -0.00
- Stochastic Oscillator
- AUST 64.82
- BLRX 10.83
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.